EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rewiring Tumor Lifelines: Translating Hypoxia- and Pseudohypoxia-Driven Angiogenesis into Therapeutic Breakthroughs

Michael Boulis iD, Fady Tawfik iD, Anitha Kota Shenoy iD

Cells · 20.07.2026 · 15 (14) · 1295

DOI: 10.3390/cells15141295 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.07.2026. Verfasst von Michael Boulis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Naresh K. Vashisht College of Medicine, Texas A&M University, Bryan, TX 77807, USA. Hauptthemen laut MEDLINE: Neovascularization, Pathologic, Neoplasms, Hypoxia. Die Arbeit nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia and the evolving concept of pseudohypoxia are critical in driving tumor angiogenesis, contributing to malignancy progression and therapeutic resistance. Angiogenesis, a common feature of many solid tumors, is promoted by hypoxia-induced overexpression of pro-angiogenic factors (e.g., VEGF, FGF) and genetic mutations (e.g., VHL, SDH) that stabilize hypoxia-inducible factors (HIF) even in normal oxygen conditions, a phenomenon known as pseudohypoxia. Recent experimental studies challenge the view that hypoxia universally enhances vessel growth. In certain models, severe oxygen deprivation impairs angiogenesis. Furthermore, tumor-mediated metabolic reprogramming can drive immune evasion via HIF stabilization in immune cells. These paradoxes, together with persistent therapy resistance and the limited effectiveness of current anti-angiogenic treatments, reveal critical gaps in our understanding of how hypoxic signaling modulates vascular and immune dynamics within the tumor microenvironment. These complexities demand more detailed exploration of underlying processes and the development of innovative therapeutic strategies. Here, we review recent mechanistic studies on tumor angiogenesis, summarizing therapeutic and diagnostic advances from both preclinical and clinical studies. We further discuss strategies to exploit hypoxic vulnerabilities, including HIF inhibitors, hypoxia-activated prodrugs, vascular normalization, combination regimens to restore immunity, biomarker-guided patient selection, and advanced hypoxia-targeted imaging to improve outcomes in angiogenesis-driven cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neovascularization, PathologicNeoplasmsHypoxiaHumansAnimalsTumor MicroenvironmentAngiogenesis InhibitorsMetabolic Reprogramming

Stichwörter der Autor:innen

HIF inhibitorsSDH mutationsVEGFVHL mutationsanti-angiogenic therapyclinical trialshypoxiahypoxia-inducible factorspseudohypoxiatumor angiogenesis

Substanzen

Angiogenesis Inhibitors

Autor:innen und Institutionen

  • Naresh K. Vashisht College of Medicine, Texas A&M University, Bryan, TX 77807, USA.
  • College of Medicine, Howard University, Washington, DC 20059, USA.
  • Department of Medical Education, Naresh K. Vashisht College of Medicine, Texas A&M University, Bryan, TX 77807, USA.

ORCID-Profile: Michael Boulis, Fady Tawfik, Anitha Kota Shenoy

Zitieren

APA

Boulis, M., Tawfik, F., & Shenoy, A. K. (2026). Rewiring Tumor Lifelines: Translating Hypoxia- and Pseudohypoxia-Driven Angiogenesis into Therapeutic Breakthroughs. Cells, 15(14), 1295. https://doi.org/10.3390/cells15141295

Vancouver

Boulis M, Tawfik F, Shenoy AK. Rewiring Tumor Lifelines: Translating Hypoxia- and Pseudohypoxia-Driven Angiogenesis into Therapeutic Breakthroughs. Cells. 2026;15(14):1295. doi:10.3390/cells15141295

BibTeX
@article{Boulis2026,
  author = {Boulis, Michael and Tawfik, Fady and Shenoy, Anitha Kota},
  title = {Rewiring Tumor Lifelines: Translating Hypoxia- and Pseudohypoxia-Driven Angiogenesis into Therapeutic Breakthroughs},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {1295},
  doi = {10.3390/cells15141295}
}
Kostenlos starten →